Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study

Kuoni, Sabrina; Steiner, Regula; Saleh, Lanja; Lehmann, Roger; Ochsenbein-Kölble, Nicole; Simões-Wüst, Ana Paula

doi:10.1016/j.biopha.2024.116177

Biomedicine & Pharmacotherapy

2024

DOI: 10.1016/j.biopha.2024.116177

|View full text |Cite

Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study

Sabrina Kuoni,

Regula Steiner,

Lanja Saleh

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Implications of pregnancy on cardiometabolic disease risk: preeclampsia and gestational diabetes

Elgazzaz,

Woodham,

Maher

et al. 2024

American Journal of Physiology-Cell Physiology

View full text Add to dashboard Cite

Cardiometabolic disorders, such as obesity, insulin resistance and hypertension, prior to and within pregnancy are increasing in prevalence worldwide. Pregnancy-associated cardiometabolic disease poses a great risk to the short and long-term well-being of the mother and offspring. Hypertensive pregnancy, notably preeclampsia, as well as gestational diabetes are the major diseases of pregnancy growing in prevalence as a result of growing cardiometabolic disease prevalence. The mechanisms whereby obesity, diabetes, and other comorbidities lead to preeclampsia and gestational diabetes are incompletely understood and continually evolving in the literature. In addition, novel therapeutic avenues are currently being explored in these patients to offset cardiometabolic-induced adverse pregnancy outcomes in preeclamptic and gestational diabetes pregnancies. In this review, we discuss the emerging pathophysiological mechanisms of preeclampsia and gestational diabetes in the context of cardiometabolic risk as well as the most recent preclinical and clinical updates in the pathogenesis and treatment of these conditions.

show abstract

Implications of pregnancy on cardiometabolic disease risk: preeclampsia and gestational diabetes

Elgazzaz,

Woodham,

Maher

et al. 2024

American Journal of Physiology-Cell Physiology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study

Cited by 1 publication

References 29 publications

Implications of pregnancy on cardiometabolic disease risk: preeclampsia and gestational diabetes

Implications of pregnancy on cardiometabolic disease risk: preeclampsia and gestational diabetes

Contact Info

Product

Resources

About